Floatz logo

G 207

Nervous System Cancer

M.D. Anderson Cancer Centergene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Nervous System Cancer cohort.

Asset / SponsorPhaseRating
CABAZITAXEL
Sanofi
Phase 1/2CCC
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
GlaxoSmithKline
D

Same molecule, other indications

G 207 is also rated in:

malignant gliomaDormant
CCC
Indicative ·
48 / 100
View asset →
supratentorial cancerDormant
CC
Indicative ·
47 / 100
View asset →
primitive neuroectodermal tumorDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →